# Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer

> **NCT05445648** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 65 (estimated)

## Conditions studied

- Urinary Bladder Neoplasms

## Interventions

- **DRUG:** Tislelizumab Injection
- **PROCEDURE:** Transurethral resection of bladder tumor
- **RADIATION:** Adjuvant radiotherapy

## Key facts

- **NCT ID:** NCT05445648
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02
- **Primary completion:** 2024-02
- **Final completion:** 2026-02
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2022-12-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445648, "Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05445648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*